£300,000 for Cancer Medicines Outcome Programme

The Scottish Government has issued a press release announcing an investment of £300,000 in 2017, as part of £1 million of funding over three years, for the Cancer Medicines Outcome Programme (CMOP). The CMOP is a three year collaboration between NHS Greater Glasgow and Clyde and the University of Strathclyde and is designed to investigate the effectiveness of medicines in the "real world".

The project will explore how to maximise the use of data sets to gather information on clinical outcomes such as survival rates, duration of therapy and treatment side effects. The programme also aims to measure the real-life impact of cancer medicines on a patient’s quality of life through the collection of Patient Reported Outcome Measures.

Shona Robison MSP, Cabinet Secretary for Health and Sport, is quoted, saying, "We’ve dramatically increased access to new medicines, particularly for cancer, due to our recent reforms and investment and Scotland is now one of the top nations in the world for accessing new medicines for cancer. Now we want to explore what more can be done. That is why we are taking forward the recommendations from Dr Brian Montgomery’s recent review into access to new medicines, in collaboration with partners and stakeholders across Scotland – including the NHS, third sector and pharmaceutical industry".

The full press release can be accessed online here.

Page published: Thu 13 April 2017

It is supported by 9 companies:

  • Amgen
  • Bayer
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Lilly
  • Novartis
  • Pfizer
  • Roche
  • Shire